<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045613</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-CS-201</org_study_id>
    <secondary_id>2019-000359-15</secondary_id>
    <nct_id>NCT04045613</nct_id>
  </id_info>
  <brief_title>Derazantinib and Atezolizumab in Patients With Urothelial Cancer</brief_title>
  <acronym>FIDES-02</acronym>
  <official_title>An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of derazantinib single-agent or
      derazantinib-atezolizumab in combination in patients with advanced urothelial cancer
      harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various
      clinical stages of disease progression and prior treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study comprises four open-label substudies in patients with advanced urothelial cancer
      harboring FGFR GA who will be treated by single-agent derazantinib or derazantinib in
      combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status,
      or patients whose disease progressed after either first-line treatment or prior treatment
      with FGFR inhibitors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) based on RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D) of derazantinib in combination with atezolizumab</measure>
    <time_frame>Approximately up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate per RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response per RECIST 1.1</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival (PFS) and PFS at 6 months</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS) and OS at 6 months</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of study treatment based on incidence of treatment-emergent adverse events</measure>
    <time_frame>Approximately up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">303</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Derazantinib [Substudy 1]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer who have progressed on at least one line of standard treatment will be treated with derazantinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib + Atezolizumab: Dose finding [Substudy 2]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding and dose expansion in patients with solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib +/- Atezolizumab: First line [Substudy 3]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer will be randomized for first-line treatment with either derazantinib alone or the recommended phase 2 dose (RP2D) for derazantinib-atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Derazantinib +/- Atezolizumab: Second line [Substudy 4]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with urothelial cancer progressing after prior FGFR inhibitor treatment will be randomized to receive either derazantinib alone or the RP2D for derazantinib-atezolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Derazantinib</intervention_name>
    <description>Substudy 1: Derazantinib will be administered orally at a dose of 300mg once per day
Substudy 2: Derazantinib will be administered orally at various dose levels
Substudy 3 and 4: Derazantinib will be administered orally at the dose of 300mg once per day as single agent or at the identified RP2D for derazantinib-atezolizumab</description>
    <arm_group_label>Derazantinib + Atezolizumab: Dose finding [Substudy 2]</arm_group_label>
    <arm_group_label>Derazantinib +/- Atezolizumab: First line [Substudy 3]</arm_group_label>
    <arm_group_label>Derazantinib +/- Atezolizumab: Second line [Substudy 4]</arm_group_label>
    <arm_group_label>Derazantinib [Substudy 1]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (drug supplied by Hoffmann-La Roche)</intervention_name>
    <description>Atezolizumab will be intravenously administered every 3 weeks at a dose of 1200mg.</description>
    <arm_group_label>Derazantinib + Atezolizumab: Dose finding [Substudy 2]</arm_group_label>
    <arm_group_label>Derazantinib +/- Atezolizumab: First line [Substudy 3]</arm_group_label>
    <arm_group_label>Derazantinib +/- Atezolizumab: Second line [Substudy 4]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or
             lower urinary tract

          -  Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or
             progressing disease

          -  Documented FGFR genetic alteration

          -  Measurable disease per RECIST 1.1

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Receipt of chemotherapy, targeted therapies, immunotherapy, or treatment with an
             investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug
             whichever is longer before the first dose of study drug.

          -  Concurrent evidence of any corneal or retinal disorder

          -  Phosphatemia greater than institutional upper limit of normal (ULN) at screening

          -  Uncontrolled tumor-related hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique Cantero, MD</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica International Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédérique Cantero, MD</last_name>
    <phone>+41 76 830 2499</phone>
    <email>frederique.cantero@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Braun, MD</last_name>
    <phone>+41 79 121 1561</phone>
    <email>stephan.braun@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTCA Clinical Research Inc., Atlanta</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHA Centre Hospitalier de l'Ardenne</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076 CEDEX</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Timone / CEPCM</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IUCT-Oncopole de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkolgiai Klinika</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bacs- Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>B.A.Z.Megyei Központi Kórház és Egyetemi Oktató Kórház</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35105</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o. o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Onkologiczny</name>
      <address>
        <city>Wieliszew</city>
        <zip>05-135</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IOB - Hospital Quiron Salud</name>
      <address>
        <city>Barcelona</city>
        <zip>8023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marques de Valdecilla University Hospital</name>
      <address>
        <city>Santander</city>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>14009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic urothelial cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>Fibroblast Growth Factor Receptor</keyword>
  <keyword>FGFR genetic aberration</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>derazantinib</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>immune checkpoint blockade</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>Tecentriq</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

